The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape

Head of Medical Evidence Generation, Pfizer

Dr. Doyle is an epidemiologist and health services researcher who specializes in studying the risks, benefits, and value of healthcare interventions. He has 25+ years experience in conducting research and leading teams covering specialties such as pharmacoepidemiology, health economics & outcomes research, and real-world evidence. He has applied these disciplines to develop novel models of market access for biopharmaceuticals, including outcomes-based agreements and innovative financing to support value-based healthcare initiatives in pursuit of the “Quadruple Aim”.

Dr. Doyle has published over 200 abstracts and peer-reviewed articles, with special concentration in oncology. He serves as the co-chair of the Health Economic Impact Steering Committee for the Alliance for Regenerative Medicine where he focuses on the value assessment of cell and gene therapy. Dr. Doyle frequently gives presentations and lectures on the above areas of expertise in both commercial and academic settings internationally. Dr. Doyle served on the faculty at Columbia University’s Mailman School of Publish Health since 2005.

Director, Value & Outcomes at Amicus Therapeutics

A seasoned healthcare ecnomics and outcomes research leader, Vera currently serves as Director of Value & Outcomes at Amicus Therapeutics. Prior to her current role, she advanced through key strategic positions at GSK, first as Director, Value Evidence and Outcomes and then as Value Evidence Leader.

Vera earned her PhD from Imperial College London, following which she served as a postdoctoral researcher at the same instituation. Her studies also include an MSc and BSc from Utrecht University.

Her experience spans health economics, market access, clinical outcomes, HTA, epidemiology, and value-based evidence – making her an authoritative and insightful speaker on value-driven strategies in drug development and market access.

Bob Powell is a clinical pharmacologist focused on “getting the dose right” from first-in-human studies through real-world use, especially for patients often under-represented in Phase 3 trials. He has led early-development and dose-selection strategy at Glaxo, Parke-Davis, and Roche, translating preclinical insights into go/no-go decisions and clinical dosing plans. At FDA/CDER’s Pharmacometrics group, he contributed to approval decisions and early-phase sponsor consultations—experience that now informs his precision-dosing research and ongoing collaborations with regulators and industry as an adjunct at UNC Chapel-Hill. His recent publications propose more precise dosing for direct-acting oral anticoagulants, including rivaroxaban and dabigatran, in atrial fibrillation. Bob has authored 100+ peer-reviewed publications.

SVP, Biometrics, Data Science and Access, Certara

As the Senior Vice President, Biometrics, Data Science and Access at Certara, Tiffany oversees global, multi-disciplinary consulting teams that focus on evidence generation and drug development throughout the medical product lifecycle. Prior to joining Certara, she served as the President at Panalgo and General Manager, HEOR and Medical Affairs at Norstella, overseeing all strategy, operations, engagement, product, and analytic support of Panalgo’s Instant Health Data (IHD) platform. Tiffany has 20 years of varied health outcomes research experience, from leading safety analyses for regulators to supporting traditional health economics outcomes research.

Tiffany received her MPH at Boston University School of Public Health and her MBA from Temple University’s Fox School of Business.